ABILIFY MAINTENA Drug Insight

“ABILIFY MAINTENA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about ABILIFY MAINTENA for schizophrenia in the seven major markets. A detailed picture of the ABILIFY MAINTENA for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ABILIFY MAINTENA for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ABILIFY MAINTENA market forecast analysis for schizophrenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia.

Drug Summary

ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, an IM depot formulation of aripiprazole, is a sterile lyophilized powder that, when reconstituted with sterile water for injection, forms an injectable suspension that can be administered monthly. ABILIFY MAINTENA is an atypical antipsychotic for treating schizophrenia.

Dosage and administration

The recommended starting and maintenance dose of ABILIFY MAINTENA is 400 mg monthly (no sooner than 26 days after the previous injection). After the first ABILIFY MAINTENA injection, administer oral aripiprazole (10–20 mg) for 14 consecutive days to achieve therapeutic aripiprazole concentrations during initiation of therapy.

Mechanism of action

The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ABILIFY MAINTENA description, mechanism of action, dosage and administration, research and development activities in schizophrenia.
• Elaborated details on ABILIFY MAINTENA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ABILIFY MAINTENA research and development activities in schizophrenia across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ABILIFY MAINTENA.
• The report contains forecasted sales of for schizophrenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for schizophrenia.
• The report also features the SWOT analysis with analyst views for ABILIFY MAINTENA in schizophrenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ABILIFY MAINTENA Analytical Perspective by DelveInsight

• In-depth ABILIFY MAINTENA Market Assessment

This report provides a detailed market assessment of ABILIFY MAINTENA for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• ABILIFY MAINTENA Clinical Assessment

The report provides the clinical trials information of ABILIFY MAINTENA for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABILIFY MAINTENA dominance.
• Other emerging products for schizophrenia are expected to give tough market competition to ABILIFY MAINTENA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABILIFY MAINTENA in schizophrenia.
• Our in-depth analysis of the forecasted sales data of ABILIFY MAINTENA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABILIFY MAINTENA in schizophrenia

Key Questions

• What is the product type, route of administration and mechanism of action of ABILIFY MAINTENA?
• What is the clinical trial status of the study related to ABILIFY MAINTENA in schizophrenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABILIFY MAINTENA development?
• What are the key designations that have been granted to ABILIFY MAINTENA for schizophrenia?
• What is the forecasted market scenario of ABILIFY MAINTENA for schizophrenia?
• What are the forecasted sales of ABILIFY MAINTENA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to ABILIFY MAINTENA for schizophrenia?
• Which are the late-stage emerging therapies under development for the treatment of schizophrenia?